By using broth microdilution methods, the in vitro activity of tosufloxacin (A-64730), a new quinolone, was compared with those of other agents, including five quinolones, against geographically diverse cystic fibrosis sputum isolates obtained from 26 cystic fibrosis centers in the United States. These included Pseudomonas aeruginosa, conventional as well as especially resistant (ceftazidime, aztreonam, gentamicin, and/or tobramycin) isolates; Escherichia coli; Pseudomonas cepacia; Staphylococcus aureus; and Haemophilus influenzae. Tosufloxacin MICs for 50 and 90% of isolates of standard P. aeruginosa were 0.5 and 2.0 mg/liter, for resistant P. aeruginosa they were 4.0 and >16.0 mg/liter, for E. coli they were <0.016 and .0.016 mg/liter, for P. cepacia they were 4.0 and 8.0 mg/liter, for S. aureus they were 0.063 and 0.063 mg/liter, and for H. influenzae they were <0.016 and 0.032 mg/liter, respectively. Tosufloxacin activities against standard and resistant strains of P. aeruginosa were similar to those of comparative quinolones. Against E. coli, tosufloxacin activity was similar to those of other quinolones. Against S. aureus, tosufloxacin activity was similar to those of trimethoprim-sulfamethoxazole and cephalexin, but tosufloxacin was more active than other agents. Against H. influenzae, tosufloxacin activity was similar to those of other quinolones. There was minor diminution of activity at pH 8.2 but major diminution of activity at pH 5.2 and at inoculum sizes of i107 CFU/ml. Activity was unaffected by sputum but was enhanced by serum and by the omission of cation supplementation. Tosufloxacin has consistent activity against common cystic fibrosis pathogens. Its high degree of activity against S. aureus with activity maintained against P. aeruginosa and other gram-negative bacteria of interest suggests that further in vitro studies and assessment of activity in in vivo models of cystic fibrosis pulmonary infections are warranted.
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Tosufloxacin, A-64730, is a new broad-spectrum fluoroquinolone agent with in vitro activity against a variety of microorganisms. These include gram-positive and gramnegative aerobic bacteria (P. Weber, G. Leturnier, A. Fremaux, P. Geslin, and Y. Boussougant, Program Abstr. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 105, 1989; J. Segreti, L. J. Goodman, E. J. Glick, and G. M. Thewholme, 29th ICAAC, abstr. no. 99, 1989), anaerobic bacteria (9) , and Chlamydia trachomatis (S. C. Lafredo, T. Fekete, and K. R. Cundy, 28th ICAAC, abstr. no. 1478, 1988). Its mechanism of action, like those of other fluoroquinolones, involves inhibition of bacterial DNA gyrase (17) . At present, there are no data available regarding the pharmacokinetic profile of this new compound in humans; however, studies in a murine model have shown that after oral administration of 100 mg/kg, peak concentrations in serum are similar to those of ciprofloxacin (2.3 ,ug/ml), with a longer elimination half-life for tosufloxacin (3.9 versus 1.2 h, respectively) (9) .
Because of their spectra of activity and oral bioavailabilities, agents from the fluoroquinolone family may play an important role in the treatment of infections in patients with cystic fibrosis (CF) (3, 4, 7, 14, 16) . This study was designed to evaluate the in vitro activity of tosufloxacin against respiratory isolates obtained from the sputum of patients with CF. We measured tosufloxacin activity under conditions that reflect those found at the sites of infection in patients with CF.
( the isolates used for comparative purposes, 0.01 ml from each microdilution well was transferred to antibiotic-free agar. Following a reincubation period of 18 to 24 h (in 10% CO2 for H. influenzae), the MBC was defined as the lowest antibiotic concentration that yielded a 99.9% kill of the initial inoculum. In these evaluations, MIC determinations of all antimicrobial agents were controlled by inclusion of reference strains: E. coli ATCC 25922, P. aeruginosa ATCC 27853, and S. aureus ATCC 29213. In all cases, these results were within one twofold dilution of the established MICs.
Variation of growth conditions. Sputa obtained by voluntary expectoration by patients with CF were pooled, homogenized in sputolysin (Calbiochem-Behring Corp., La Jolla, Calif.), sonicated, and centrifuged, and the supernatant was sterilized by membrane filtration. Sterile pooled sputum was then aseptically added in a 1:1 dilution to appropriately supplemented Mueller-Hinton broth. By using the sputumMueller-Hinton broth medium as a diluent, various antimicrobial agent test panels were prepared, and MICs and MBCs were determined by using selected isolates. Similarly, pooled human sera, which were obtained from patients with CF, were used in a 1:1 ratio with Mueller-Hinton broth for susceptibility testing.
Selected isolates, consisting of P. aeruginosa (n = 6), P. cepacia (n = 2), E. coli (n = 3), and S. aureus (n = 3) at a final inoculum density of 106 CFU/ml, were exposed to tosufloxacin at pHs 5.2, 6.2, 7.2, and 8.2. The pH was adjusted with 1 M NaOH or 1 M HCl. Similarly, these Table 1 . Tosufloxacin activity against P. aeruginosa isolates was similar to that of norfloxacin, twofold greater than those of ofloxacin and enoxacin, and fourfold less than that of ciprofloxacin. Against the resistant isolates, tosufloxacin activity was similar to those of the other quinolones. Against P. cepacia, results were similar to those obtained for ciprofloxacin, ofloxacin, norfloxacin, and enoxacin. Against H. influenzae, tosufloxacin was eightfold more potent than enoxacin but had activity similar to those of the other comparative quinolones. Against E. coli, tosufloxacin activity was similar to those of the other quinolone agents.
Tosufloxacin activity against methicillin-susceptible S. aureus isolates was similar to that of the combination trimethoprim-sulfamethoxazole and to that of cephalexin but was 8-to 32-fold greater than those of the comparative quinolones and nafcillin.
Effects of various growth conditions on tosufloxacin activity. Table 2 shows the effect of changes (median) in the pH of the Mueller-Hinton broth on the MIC of tosufloxacin for P. aeruginosa. Reduction of the pH to 6.2 did not affect the MICs for P. aeruginosa, P. cepacia, S. aureus, E. coli, or H. influenzae. When the pH was reduced to 5.2, the MICs for 8 of 14 mnicroorganisms tested increased substantially. When the pH was increased to 8.2, the MICs for P. aeruginosa and one isolate of S. aureus increased 4-to 32-fold but remained constant for E. coli, P. cepacia, and other S. aureus strains. Ciprofloxacin, which was used for comparative purposes, showed a similar trend under acidic and alkaline conditions.
Tosufloxacin activity was stable up to an inoculum size of 106 CFU/ml but was considerably reduced at an inoculum of 2107 CFU/ml (Table 3) . Its activity was not affected when tested in sputum from patients with CF but was increased in human serum (Table 4) . Tosufloxacin activity was increased 2-to 256-fold by omitting cation supplementation.
DISCUSSION
Progressive pulmonary infection is the primary cause of morbidity and mortality in patients with CF (3) . Treatment of these infections is problematic because of characteristics of the disease process at the site of infection that often preclude effective antimicrobial action (3) .
Tosufloxacin activity against gram-negative and grampositive isolates that were obtained from patients without CF has been excellent (8) (9) (10) . In our study, tosufloxacin activity against conventional P. aeruginosa isolates from patients with CF was similar to those of norfloxacin and imipenem; greater than those of ofloxacin, enoxacin, gentamicin, tobramycin, ceftazidime, and aztreonam; but two dilutions less than that of ciprofloxacin. No differences between mucoid and nonmucoid strains were noted. Against resistant P. aeruginosa isolates, tosufloxacin activity was similar to those of the comparative quinolones. These results are consistent with those of previous investigations in which cross resistance among fluoroquinolones, whether by alterations in the outer membrane proteins (5) or by changes in the configuration of bacterial DNA gyrase (4, 15) , has been common. Against P. cepacia, E. coli, and H. influenzae, tosufloxacin activity was comparable to those of other quinolones. However, tosufloxacin activity against S. aureus was higher than those of the comparative quinolone agents and nafcillin. This result, which was similar to those of previous observations for strains from patients without CF (8) (9) (10) 18) , is encouraging in that mixed S. aureus-P. aeruginosa pulmonary infection remains a common etiology in patients with CF, affecting more than 20% of patients with CF in the United States (Cystic Fibrosis Foundation, unpublished data).
Tosufloxacin bactericidal activity was not influenced by CF sputum but was enhanced in the presence of human serum. Results of previous studies (6, 16) with other quinolones support these findings with CF sputum but are different from the results obtained when human serum was used (4, 8, 9) . Our findings could be the result of an interaction between tosufloxacin and nonspecific bactericidal factors in serum that are directed against the tested microorganisms obtained from the population with CF. Additional experiments are necessary to fully evaluate this observation.
The significant reduction in the activity of tosufloxacin when tested at pHs 5.2 and 8.2 and at an inoculum density of i107 CFU/ml is similar to results obtained with other quinolone agents (1, 2, 4). Its clinical relevance must be evaluated in future therapeutic trials.
An antagonistic effect of Ca2+ and Mg2+ on the in vitro activity of tosufloxacin was noted. Although this observation is consistent with the reports of other investigators (1, 8, 9) , its clinical significance is not clear and should be evaluated in specific clinical trials.
In view of its broad activity against gram-negative bacilli, and especially against S. aureus, and the minimal effect of sputum obtained from patients with CF, tosufloxacin appears to be a potentially useful agent against the pathogens that produce bronchopulmonary infections in patients with CF. Further kinetic and animal model studies are therefore warranted as a prelude to possible clinical trials in humans. 
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